Clinical Practice Guideline on the Choice of First Antipsychotic Medicine for Females Experiencing a First-Episode of Psychosis - PubMed
5 days ago
- #first-episode psychosis
- #antipsychotic medicine
- #patient-centered care
- Early intervention in first-episode psychosis (FEP) is crucial for long-term outcomes, with antipsychotic medicines being a primary treatment option.
- Existing clinical practice guidelines lack sex-specific recommendations, despite females having distinct vulnerabilities to antipsychotic side-effects like hyperprolactinemia and cardiometabolic issues.
- An international multidisciplinary panel developed a guideline using the GRADE-ADOLOPMENT process and AGREE II framework, prioritizing patient outcomes and side-effect profiles.
- Antipsychotics with high risks (e.g., first-generation antipsychotics, olanzapine, risperidone) are not recommended first-line for females due to adverse effects.
- Aripiprazole is recommended as the preferred first-choice due to its favorable prolactin and cardiometabolic profile.
- Alternative low or low-to-medium risk options are suggested for adults and adolescents, supported by shared decision-making tools.
- This is the first guideline focusing on antipsychotic choice for females with FEP, aiming to improve treatment acceptability, adherence, and equity.